Affiliation:
1. Department of Biomedical Engineering
2. Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
Abstract
Purpose of review
This review summarizes the pathophysiology and potential therapeutic options for treatment of multiple sclerosis, a common neuronal demyelinating disorder affecting 2.2 million people worldwide. As an autoimmune disorder, multiple sclerosis is associated with neuroinflammation and increased permeability of the blood–brain barrier (BBB), although the cause linking multiple sclerosis with compromised barrier function remains ill-defined. It has been previously shown that coagulation factors, including thrombin and fibrin, exacerbate the inflammatory processes and permeability of the BBB.
Recent findings
Increased levels of the coagulation factor (F) XII have been found in patients presenting with relapsing–remitting multiple sclerosis, with a deleterious role for FXII being validated in murine model of multiple sclerosis, experimental autoimmune encephalitis (EAE). Recent work has uncovered a role for the major substrate activated by FXII and thrombin, FXI, in the disorder of EAE. The study found that pharmacological targeting of FXI decreased clinical symptoms, lymphocyte invasion, and white matter destruction in a multiple sclerosis model.
Summary
This review emphasizes the role of FXII and FXI in regulating barrier function and the immune response in neuroinflammation. These new findings broaden the potential for therapeutic utility of FXI inhibitors beyond thrombosis to include neuroinflammatory diseases associated with compromised BBB function, including multiple sclerosis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference64 articles.
1. Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective;Filippi;J Neurol,2023
2. Diagnosis and treatment of MS in patients suffering from various degrees of the disease with a clinical approach: the original article;Hossein;J Pharm Negat,2022
3. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS;Huijbregts;Neurology,2004
4. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy;Ghasemi;Cell J,2017
5. 48 - Mechanisms of autoimmunity;Cottrell;Clinical immunology,2013